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tence compared to those who started on a generic and switched to a brand.
CONCLUSIONS: Initiating or switching to generic therapy is associated with signif-
icantly higher compliance and greater therapy persistence compared to initiating
or switching to brand medications.
PIH30
ASSESSING INCONSISTENCIES IN ADHERENCE RESEARCH: A SYSTEMATIC
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OBJECTIVES: Non-adherence to prescription medication is a serious problem. Ac-
curate assessment of adherence is important for improving patients’ health out-
comes and informing decisions made by providers and payers. This study exam-
ined how adherence was defined, measured, and reported in the scientific
literature. METHODS: A systematic review of studies reporting on adherence to
prescription medication for chronic diseases was conducted. Embase® and MED-
LINE® databases were searched. In addition, bibliographies of identified review
papers were assessed for inclusion. Mean overall adherence was estimated using a
random effects model. RESULTS: The review included 266 studies that met pre-
defined inclusion criteria. The definition of non-adherence varied across studies;
73.6% of all studies defined non-adherence as missed/skipped doses only, while
24.3% defined it as discontinuation of therapy only, and 2.1% defined it as either.
Adherencewas recordedusing different tools including claimsdata (55.2%), patient
self-reports (30.5%), pill counts (12.8%), and laboratory tests (1.5%). Furthermore,
included studies used various metrics to assess determinants of adherence, and
some studies used more than one measure. The most commonmetrics were odds
ratios (65.6%), regression coefficients (13.0%), hazard ratios (11.2%), and relative
risks (5.4%). Themeta-analysis showed that themean overall adherence was high-
est in studies that defined non-adherence as missed/skipped doses only (51.7% of
all participants). Mean adherence in studies defining non-adherence as discontin-
uation of therapy only and in studies defining it as missed/skipped doses or dis-
continuation of therapy was 45.4% and 45.0%, respectively. CONCLUSIONS: Incon-
sistencies in the adherence literature pose a challenge to the interpretation,
usefulness, and synthesis of adherence data. There is a clear need formethodolog-
ical standardisation in adherence research and assessment.
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OBJECTIVES: To assess the impact of reducing the frequency of oral therapies from
multiple-dosing schedules to a once-daily (od) dosing schedule on adherence, com-
pliance, and the associated economic impact.METHODS: All relevant studies were
searched using electronic databases (MEDLINE® and Embase®). The studies as-
sessing adherence with od, twice-daily (bid), thrice-daily (tid), and four-times daily
(qid) dosing schedules, and costs associated with optimal/suboptimal adherence
among patients with acute and chronic diseases, were included. There was no
restriction on the treatments assessed other than that they were delivered orally.
Comparisons of effect estimates across studies were pooled and analyzed using a
DerSimonian and Laird random-effects model. RESULTS: Forty-three studies met
the inclusion criteria of the review, ofwhich 33 studies compared once-daily dosing
schedulewithmultiple-dosing schedules. Data on adherence and compliancewere
available for studies in depression, HIV, hypertension, and respiratory tract infec-
tions (RTIs). Among these conditions, the overall results indicated that od schedule
was associated with higher adherence rates [Odds Ratio (OR): 2.34; 95% Confidence
Interval (CI): 1.31, 4.17; p0.004 for od versus bid/tid dosing] and compliance rates
(OR: 5.76; 95% CI: 1.89, 17.57; p0.001 for od versus bid dosing) compared with
multiple-dosing schedules. From a health economic perspective, it was observed
that higher adherence rates with od schedule (relative to multiple-dosing sched-
ules) prescribed in cardiovascular disorders, renal transplant, pain, RTIs, and ul-
cerative colitis were associated with lower costs of healthcare resource utilization.
For example, treatment costs in renal transplant patients demonstrated total, per-
patient cost savings of $9411 over a 5-year time horizonwith od regimen compared
with bid regimen. CONCLUSIONS: The present evidence base suggests that reduc-
ing the dose frequency from multiple dosing to once-daily dosing schedule could
improve adherence and compliance among patients with acute and chronic dis-
eases. Improving adherence was associated with further decreases in health care
costs.
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OBJECTIVES: Non-adherence to treatment predicts poorer health status. Patient
characteristics underlying intentional (INA) and unintentional (UNA) non-adher-
encewere analyzed among eleven costly chronic conditions.METHODS:Data from
U.S. 2011 National Health and Wellness Survey included 30,981 (of 75,000) respon-
dents reporting prescriptions for: asthma, pain, congestive heart failure, COPD,
diabetes, hypertension, depression, bipolar disorder, peripheral vascular disease,
transient ischemic attack, and stroke. Morisky Medication Adherence Scale items
were summed to create INA (“stop taking medicine when feeling better” and
“. . .when feeling worse”) and UNA (“forget to take medicine” and “careless about
taking medicine”) scores ranging from 0adherence to 2high non-adherence.
Across conditions, two logistic regressions predicted INA and UNA (1 vs. 0) from
gender, age, marital status, college education, income, race/ethnicity, exercise12
timesmonthly, alcohol consumption2 timesweekly, cigarette smoking, employ-
ment, health insurance, BMI category, and adjusted Charlson Comorbidity Index
(CCI) score. RESULTS: Adjusting for covariates, significant predictors of INA and
UNA (odds ratios in parentheses for INA and UNA, respectively), were: female
gender (1.32/1.09), younger age (1.04/1.02), education (non-significant [n.s.]/1.13),
employment (n.s./1.13), uninsured status (1.24/n.s.), income $50k (vs. $50k-
$75k: 1.15/n.s.; vs. $75k: 1.20/1.11), Hispanic (1.60/1.20), African American (1.47/
1.21), or other (1.52/1.28) race/ethnicity (vs.White), non-exercise (1.19/1.39), alcohol
consumption (1.12/1.16), smoking (1.25/n.s.), overweight (0.90/1.16), obesity (0.81/
1.37), and high CCI (1.03/1.03); all p.05. CONCLUSIONS: Women, non-Whites,
younger, and poorer respondents, non-exercisers, alcohol consumers, and more
comorbid respondents were at greater risk of non-adherence. Obesity/overweight
predictedhigherUNAbut lower INA risk, perhaps fromobstacles to adherence (e.g.,
complex treatment regimens) but more adherent intentions due to obesity-related
mortality risk. Employment and education were associated only with UNA (per-
haps due to difficulty tracking treatment regimens while engaged in complex oc-
cupations). Smoking and uninsured status were associated only with INA. Simpli-
fied treatments may improve UNA while better access may reduce non-adherence
overall.
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OBJECTIVES: Compliance or adherence to regimens and persistence over time are
common concerns among doctors. The impact of oral once-daily [QD] or twice-
daily [BID dosing regimen on adherence and persistence is unclear, and may po-
tentially affect clinical and economic outcomes. This review aims to identify stud-
ies that identified the impact of QD vs. BID dose regimens of oral treatments on
adherence and persistence in several disease areas that require chronic medica-
tion use.METHODS: Relevant articles were identified through a systematic litera-
ture review from PubMed (2000-2011) using the terms adherence, oral, administra-
tion and dosage, QD, BID, once daily, twice daily, and treatment. Another search
explored the secondary and tertiary references of relevant studies identified
through the bibliographies of articles found in the primary search. RESULTS: Re-
search articles (N16) that met the search criteria comprised the following disease
areas: HIV/AIDS (10 articles), diabetes, ulcerative colitis (2), depression, hyperten-
sion and chronic heart failure. 63% (10/16) of the studies observed improvement on
adherence with the oral QD treatment in comparison to the BID regimen. Of those,
6 were for HIV drugs, 1 for hypertension, 1 for ulcerative colitis, 1 for diabetes and
1 for depression. Articles evaluating drugs for the treatment of ulcerative colitis,
HIV (4) and chronic heart failure found no impact on adherence. Persistence was
measured in 25% (4/16) of the studies, identified the following therapeutic areas:
depression, diabetes and HIV. 50% (2/4) found significantly greater persistence
among patients in the QD regimen versus BID regimens. Studies on HIV medica-
tions did not find any impact on persistence. CONCLUSIONS: Themajority of stud-
ies evaluating adherence of oral QD versus BID treatments for long-term drug
treatments observed improvement of adherence with QD versus BID treatment.
The impact of oral drug dosing frequency on persistence remains unclear and can
vary by therapeutic areas.
PIH34
IMPACT OF MEDICARE PART D COVERAGE GAP ON BENEFICIARIES’ ADHERENCE
TO PRESCRIPTION MEDICATIONS
Desai U1, Carroll NV2
1Analysis Group, Inc., Boston, MA, USA, 2Virginia Commonwealth University, Richmond, VA,
USA
OBJECTIVES: It is important to study the extent to which Medicare Part D’s unique
benefit structure (with a gap in the middle) affects seniors’ adherence to prescrip-
tion medications. Therefore, this study had following objectives: 1) To identify
characteristics of beneficiaries reaching and not reaching the coverage gap, and 2)
To study the impact of a complete gap in coverage on beneficiaries’ adherence to
prescriptionmedications.METHODS: This was a retrospective quasi-experimental
analysis with matched control group using a nationally representative sample of
Part D enrollees of stand-alone prescription drug plans (PDPs) from2008Centers for
Medicare andMedicaid (CMS) Part D and summary datasets. In addition to studying
differences in characteristics of those who did and did not reach the coverage gap
in 2008, adherence to oral medications taken from one or more of the seven pre-
defined therapeutic classes was measured using Medication Possession Ratio
(MPR). Appropriate statistical tests for significance were performed using SAS 9.1.
RESULTS: A quarter of our sample (24.42%) reached the coverage gap in 2008,
mostly by end of September. Of these, 12.10% (2.97% of the total sample) reached
the catastrophic coverage phase. Although the two groups had similar demo-
graphic attributes, beneficiaries reaching the coverage gap had higher prescription
medication use compared to those not reaching the coverage gap (11.25(4.63) vs.
7.39(3.75)). Beneficiaries reaching the gap experienced significantly greater reduc-
tions in adherence (3.00% more for beta-blockers to 9.00% more for oral anti-dia-
betic agents, p-value0.0001), compared to those not reaching the gap. During the
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coverage gap period, a considerable proportion of beneficiaries stopped taking
medications in both the groups and the proportion of beneficiaries considered
adherent (MPR0.80) also dropped for both the groups. CONCLUSIONS: Medicare
Part D beneficiaries face significant barriers to adherence, especially those reaching
the coverage gap. Interventions to improve adherence should target all beneficia-
ries, particularly those using multiple medications.
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OBJECTIVES: To establish any impact of the high deductible Consumer Directed
Health Plans (CDHP) on the overall utilization and adherence outcomes for some
key therapeutic classes one year post implementation.METHODS: CVS Caremark
pharmacy claims data (7/1/2008 – 7/1/2011) was analyzed. This study was designed
as a retrospective pre-post cohort study. For the clients who implemented CDHP in
2010, we compared overall utilization and adherence (pre- and post- implementa-
tion date) between patients who opted into CDHP vs. those who stayed in Tradi-
tional (non-CDHP) plans for specific therapies: angiotensin-converting enzyme in-
hibitors (ACEIs) or angiotensin-II receptor blockers (ARBs), HMG-CoA reductase
inhibitors (statins), and Biguanides (e.g. metformin), identified based on the GPI-4
and GPI-6 codes (Biguanides: 2725/279970/279980- ARBs: 3615/369930/369940-
ACEIs: 3610/369930/369940- STATINS: 3940- PPIs: 4927). Bi-variate and multi-vari-
ate analyses, including mixed effects, were conducted using SAS Version 9.1 (9.2)
with SAS/STAT. RESULTS: The total of 132,846 patients met inclusion criteria. Ge-
neric Dispense Rate (GDR) increased by 5.9% (p0.001) in the CDHP cohort com-
pared to the 4.7% (p0.001) increase in the Traditional cohort between the pre and
post periods. No significant differences were observed in the 90-day supply distri-
bution between the two cohorts. Observed (unadjusted) 12-months adherence did
not change significantly post CDHP implementation in the 4 key therapeutic class-
es: STATINS, ACEIs, ARBs, and BIGUANIDES. The utilization of PPIs decreased post-
implementation by 0.34% (p0.05) in the CDHP cohort, while it increased by 2.5%
(p0.001) in the Traditional cohort. CONCLUSIONS: CDHPmembers were observed
to behave in a cost-effective manner. Post-implementation increase in GDR in the
CDHP cohort was 1.2% (p0.001) higher compared with the members in the Tradi-
tional cohort. The CDHP cohort demonstrated decreased utilization of some non-
essential medications, but their observed adherence to key therapies was unaf-
fected.
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OBJECTIVES: Patient-centered care is seen as a critical factor in a high-perfor-
mance health care system. We considered a randomized decision-situation in
which the available information is given by three hypothetical health states (infor-
mation sets: consider youhave beendiagnosedwith diabetes, lung cancer, or based
on the status quo of the respondent).METHODS:Within a discrete-choice experi-
ment (DCE) 21 characteristics of a healthcare delivery system are being used to
construct 4 DCEs based on thematic mapping (patient-involvement; point of care;
personnel; organization). Each DCE included six attributes with three specific lev-
els. Furthermore respondents were randomly assigned and asked to make their
decisions based on different information sets. RESULTS: For the N3900 respon-
dents the feature “out-of-pocket costs” was the important attribute across all 4
DCEs (DCE-1 coefficient, 0,6550; DCE-2 coefficient, 0,8624; DCE-3 coefficient, 0,6991;
DCE-4 coefficient, 0,7926). Only “multidisciplinary care” in DCE-3 (Personnel)
scored higher than cost with a coefficient of 0,7081. In DCE1 regarding patient-
involvement, “trust and respect” (0,6187) and in DCE 2 addressing preferences at
the point of care, “shared-decisionmaking” (0,7125)were of greatest importance. In
DCE 4 the attribute “treatment guidelines” (0,4682) was of high importance. The
analysis showed that the relevance of the “out-of-pocket cost” changed when re-
spondentswere asked to consider their responses in the context of diabetes or lung
cancer diagnosis (status quo: 0.6749; diabetes: 0.81145; lung cancer: 0.50431). Fur-
thermore, the feature “trust and respect” (status quo: 0.70338; diabetes: 0.65555;
lung cancer: 0.6369) was also less valuable when participants assumed a worse
health state. CONCLUSIONS: The study aimed to close the gap between simplistic
representations of patient preferences in today’s health care systems and the com-
plexity of actual patient decision-making processes by using the explanatory
power of DCEs. Understanding how patients and stakeholders perceive and value
different aspects of coordinated care is vital to the optimal design and evaluation of
programs.
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OBJECTIVES:This study aims to: identify patient preferences for prescription-med-
ication information in terms of temporal framing (short- vs. long-term outcomes)
and examine factors associated with such information preferences. METHODS: A
total of 12,689 surveys were obtained from the Harris Interactive Chronic Illness
Panel, a nationally-representative, Internet-based panel of adults with chronic dis-
ease. Respondents were asked to rank order their preferences for prescription-
medication information in terms of information that underscored short- versus
long-term health outcomes. Logistic regression was used to examine factors asso-
ciated with first-declared preference for temporal framing. Independent variables
were demographics and multi-item scales assessing medication beliefs (perceived
necessity, perceived concerns, perceived affordability, patient knowledge) and
present orientation as measured by the Concern for Future Consequences scale.
RESULTS: Average age was 60 (range of 40-92), 52% were female, and 92% were
Caucasian. A full 84% of respondents preferred prescription-medication informa-
tion about long-term health outcomes. Preferences for long-term outcome infor-
mation were significantly associated (p  0.01) in multivariate models with older
age, higher income, having drug-insurance benefits, higher perceived affordability,
higher perceived necessity, and lower present-time orientation. For example, per-
sons with high perceived medication affordability were 1.9 times more likely to
prefer information about long-term health outcomes compared to those with low
perceived affordability. Persons with high perceived need for medications were 1.6
times more likely to prefer information about long-term health outcomes com-
pared to thosewith lowperceived need. Personswith lowpresent orientation twice
as likely to prefer information about long-termhealth outcomes compared to those
high in present orientation. CONCLUSIONS: Information about the long-term ef-
fects of prescriptionmedicationswas themost preferred information expressed by
12,689 adults with chronic disease and was influenced significantly by medication
beliefs and present orientation. Providers, manufactures, and payers should ac-
knowledge these temporal preferences when developing patient-education mate-
rials about prescription medications.
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OBJECTIVES: The Beliefs about Medication Questionnaire (BMQ) is a measure of
patients’ medication beliefs (perceived need for medications and perceived medi-
cation concerns), and it has been used widely in investigations of medication ad-
herence. To date, there has been little assessment of the relative importance of
necessity vs. concerns in determining medication adherence. Using a systematic
literature review and subsequentmeta-analysis, this study evaluates the impact of
BMQ necessity, concerns, and necessity-concerns differential as a predictor of
medication adherence.METHODS: Articles were identified through searches con-
ducted on MEDLINE, CINAHL, Psych Info, EMBASE, International Pharmaceutical
Abstracts, PubMed, and review of reference citations. Methodological variables,
effect sizes of associations, diseases, and measures of adherence were abstracted
from each eligible article. Studies were categorized by BMQ measures (necessity,
concerns, and the differential), statistical significance (bivariate or multivariate
significance, insignificance, or not applied), disease category, and adherence-out-
come metric. The relative impact of BMQ measures on adherence across different
categories was assessed. RESULTS: Across 77 studies, significant multivariate as-
sociations were reported between adherence and perceived concerns (57.4%), per-
ceived necessity (75.6%), and the differential (88.9%). Two-thirds of the 33 multi-
variate analyses demonstrated higher effect sizes (odds ratios or standardized
regression coefficients) between necessity and adherence than between concern
and adherence. There was wide variation between BMQ measures and adherence
across diseases and adherence metrics. For example, necessity was significantly
associated with adherence in 100% of diabetes studies but 0% of renal studies.
Self-reported adherence metrics and pill counts had the lowest and highest rates,
respectively, of statistical significance with BMQ. CONCLUSIONS: Perceived need
formedications is amore potent predictor of adherence thanmedication concerns.
Perceived need formedication is amutable patient belief. Adherence interventions
may improve their effectiveness if perceived need for medications became a cen-
tral theoretical and interventional focus.
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OBJECTIVES: To compare the feasibility and reliability of the binary discrete choice
experiment (DCE) and themultiprofile case of best-worst scaling (BWS) techniques
in eliciting preferences for the EQ-5D-5L. METHODS: Forty-eight EQ-5D-5L health
states (HS) were selected using a Bayesian efficient design and grouped into 24
pairs for DCE tasks and eight sets for BWS tasks (each set has threeHS). Participants
completed 12 pairs and eight sets in randomorder. Time to complete each taskwas
recorded. Participants were asked to rank each HS using a visual analogue scale
(VAS). Each participant completed, for a second time, 3 DCE pairs and 2 sets of the
BWS tasks randomly selected from the original pairs and sets, respectively. Partic-
ipants answered questions about the difficulty in imagining EQ-5D-5L HS and in
completing the tasks. A conditional probit model was used to estimate latent util-
ities for the EQ-5D-5L HS which were subsequently rescaled to facilitate the
comparison. RESULTS:One hundred persons participated (mean age: 45 years, 66%
female, 75% well-educated). Mean time to complete 12 DCE tasks was 7.7 minutes
and 10.1 minutes for eight BWS tasks. Some level of difficulty imagining the EQ-
5D-5LHSwas reported by 70%of participants. Only 13%of the participants reported
no difficulty when choosing between two HS or from three HS. The intraclass
correlation coefficient (ICC) was 0.53 for DCE tasks and 0.45 for BWS tasks. The
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